Emerging Australian biotechnology company Chimeric Therapeutics (ASX:CHM) has announced the appointment of an experienced industry executive as its new CEO.
The company, which is developing CAR-T therapies, has announced the elevation of Jennifer Chow to CEO. She has most recently served as the company's chief operating officer.
Prior to joining Chimeric, Ms Chow was head of global marketing, analytics and commercial operations at Kite Pharmaceuticals.
Gilead acquired Kite for US$12 billion in 2017 for its portfolio of cell therapies, including YESCARTA (axicabtagene ciloleucel) that was recently funded in Australia.
At Kite, Ms Chow was responsible for assessing and prioritising research and external assets for development and global commercialisation.
Ms Chow has more than 20 years of commercial strategy and marketing experience focused on cellular therapy, haematology and oncology.
She was previously global cell therapy commercial lead at Celgene and was responsible for designing and developing the global CAR T commercial strategy and operating model. Ms Chow was also formerly at Roche, Nycomed (Takeda) and Schering Canada.
“We are delighted to announce the appointment of Jennifer as MD & CEO. During her time with Chimeric thus far as COO, Jennifer has demonstrated outstanding dedication and leadership while importantly proving to be exceedingly knowledgeable in the field of cell therapy,” said Paul Hopper, executive chairman of Chimeric Therapeutics.
“The team we’ve been able to assemble at Chimeric brings deep scientific & commercial cell therapy expertise to the business and gives us great confidence moving forward under Jenn’s leadership.”
